Srikripa Devarakonda
Stock Analyst at Truist Securities
(1.98)
# 3,001
Out of 4,842 analysts
63
Total ratings
32.79%
Success rate
-3.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Hold | $72 → $73 | $66.04 | +10.54% | 10 | May 27, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $7.50 | +46.67% | 1 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $975 → $940 | $605.39 | +55.27% | 7 | Apr 30, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $132.75 | +49.91% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $14.02 | +78.32% | 5 | Apr 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $47.58 | +59.73% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $722.57 | +43.65% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $185.62 | +16.91% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $23.45 | +36.46% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $14.57 | +243.17% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $29.84 | +50.83% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $30.25 | +75.21% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.49 | +3,524.16% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $7.77 | +93.05% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $10.64 | +238.35% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $31.31 | +123.57% | 4 | May 29, 2024 |
Incyte
May 27, 2025
Maintains: Hold
Price Target: $72 → $73
Current: $66.04
Upside: +10.54%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $7.50
Upside: +46.67%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $975 → $940
Current: $605.39
Upside: +55.27%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $132.75
Upside: +49.91%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $14.02
Upside: +78.32%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $47.58
Upside: +59.73%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $722.57
Upside: +43.65%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $185.62
Upside: +16.91%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $23.45
Upside: +36.46%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $14.57
Upside: +243.17%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $29.84
Upside: +50.83%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $30.25
Upside: +75.21%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.49
Upside: +3,524.16%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $7.77
Upside: +93.05%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $10.64
Upside: +238.35%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $31.31
Upside: +123.57%